Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$125 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-65 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.8
Industry P/E
--
EV/EBITDA
0.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$3.4
EPS
$-2.4
Face value
--
Shares outstanding
47,166,400
CFO
$-309.05 Mln
EBITDA
$-381.67 Mln
Net Profit
$-371.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kinnate Biopharma Inc (KNTE)
| 11.8 | 2.3 | 6.4 | -57.6 | -56.0 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
|---|---|---|---|
|
Kinnate Biopharma Inc (KNTE)
| -61.1 | -65.6 | -55.5 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kinnate Biopharma Inc (KNTE)
|
2.7 | 125.0 | 0.0 | -112.7 | -- | -58.9 | -- | 0.8 |
| 0.3 | 34.5 | 0.0 | -88.0 | -- | -39.7 | -- | 0.2 |
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated... fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. Read more
President, CEO & Director
Mr. Nima Farzan M.B.A.
President, CEO & Director
Mr. Nima Farzan M.B.A.
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Kinnate Biopharma Inc (KNTE) is $2.65 (NASDAQ) as of 03-Apr-2024 16:00 EDT. Kinnate Biopharma Inc (KNTE) has given a return of -56.01% in the last 3 years.
Since, TTM earnings of Kinnate Biopharma Inc (KNTE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.99
|
0.70
|
|
2022
|
-2.35
|
1.20
|
|
2021
|
-8.72
|
2.44
|
|
2020
|
-7.86
|
0.71
|
|
2019
|
--
|
--
|
The 52-week high and low of Kinnate Biopharma Inc (KNTE) are Rs -- and Rs -- as of 05-Apr-2026.
Kinnate Biopharma Inc (KNTE) has a market capitalisation of $ 125 Mln as on 15-Apr-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Kinnate Biopharma Inc (KNTE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.